A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder

Documenti analoghi

• A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
  di: Gommoll, Carl P., et al.
  Pubblicazione: (2014)
• Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study
  di: Bakish, David, et al.
  Pubblicazione: (2014)
• Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
  di: Mago, Rajnish, et al.
  Pubblicazione: (2013)
• Erratum to: Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
  di: Mago, Rajnish, et al.
  Pubblicazione: (2013)
• Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials
  di: Montgomery, Stuart A., et al.
  Pubblicazione: (2014)